Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4329090 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| LY4329090 Part A | EXPERIMENTAL | Participants will receive LY4329090 administered subcutaneously (SC) |
| Placebo Part A | EXPERIMENTAL | Participants will receive placebo administered SC |
| LY4329090 Part B | EXPERIMENTAL | Participants will receive LY4329090 administered SC |
| Placebo Part B | PLACEBO_COMPARATOR | Participants will receive placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY4329090 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Participant must be 18 (21 for Singapore site) to 65 years of age, inclusive, at the time of signing the informed consent. * Are overtly healthy with no comorbidities related to body mass index (BMI). * Have a BMI between 27.0 kilograms per square meter (kg/m²) and 40.0 kg/m²,...
Top 20 of 36 competitors
LY4329090 is an investigational small molecule being studied for the treatment of obesity and overweight in adults who are otherwise healthy. It is in Phase 1 clinical development and has not been approved for any use. Eli Lilly and Company is developing the drug.
LY4329090 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 clinical program evaluating the drug in obesity and overweight.
LY4329090 is in Phase 1 clinical development. The program currently includes one recruiting Phase 1 trial in participants with obesity or overweight. The drug is investigational and has not been approved by the FDA or any other regulatory agency.
LY4329090 is being evaluated in one Phase 1 trial, NCT07808073, titled A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy. The trial is recruiting, plans to enroll 184 participants, and is being conducted in the United States and Singapore.
The Phase 1 trial NCT07808073 is a randomized, double-blind, placebo-controlled study of LY4329090 in adults aged 18 years and older with obesity or overweight who are otherwise healthy. It plans to enroll 184 participants across sites in the United States and Singapore.